Company Profile

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990 · HK
Industry
Pharmaceuticals
Exchange
HK
Current Price
HK$419
Jun 25, 2026 close
Fair Buy
≤ HK$280
Margin-of-safety entry
Baillie Growth Score
47/100
Weak
Intrinsic Value · Three-Tier Range Current price HK$419 · Within the fair intrinsic-value range

Composite valuation range · conservative HK$260–HK$280 / fair HK$390–HK$560 / optimistic HK$660–HK$705. At HK$419, Within the fair intrinsic-value range.

Recent developments
May 21, 2026 Product Confirmed

Phase III sac-TMT trial versus chemotherapy in first-line advanced TNBC met PFS primary endpoint

A Phase III trial of sac-TMT versus chemotherapy as first-line treatment for advanced TNBC met its PFS primary endpoint.

Possible impact:May affect expectations for sac-TMT label expansion and commercial potential.

Kelun-BiotechView source
Mar 24, 2026 Earnings Confirmed

Kelun-Biotech announced 2025 annual results with multiple products launched and tiered pipeline progress

Kelun-Biotech announced 2025 annual results, highlighting multiple product launches and progress across a tiered pipeline.

Possible impact:May affect market views on revenue growth, R&D spending and pipeline execution.

Kelun-BiotechView source

Automatically summarized from public sources; for context only, not investment advice.

About the company

Company overview coming soon.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990 · HK
Hold
Kelun-Biotech: A Commercializing China ADC Franchise Priced for Much of Its sac-TMT and MSD Global Success

Kelun-Biotech is a commercial-stage China ADC developer whose equity value is dominated by its sac-TMT (TROP2) franchise in Greater China plus ex-China royalty economics from MSD. In 2025 product sales inflected to RMB542.7m within RMB2.06bn total revenue and the balance sheet held RMB4.56bn cash with no borrowings, yet the company still posted a RMB382.0m net loss as nearly all equity value concentrates in one molecule. Rating Hold: a real ADC franchise is forming, but at HK$419 the stock already prices in much of the sac-TMT China plus MSD global success path and offers no margin of safety.

Pharmaceuticals Baillie 47 Jun 25, 2026